A Multicenter, Randomized, Double Blind, Placebo Controlled, Therapeutic Confirmatory Trial(Phase 3) to Evaluate Efficacy and Safety of CWP-0403 in Type 2 DM Patients (CWP-DIANA-301)

NCT01529528 Phase 3 COMPLETED

This trial is to evaluate the efficacy and safety of CWP-0403 at 100 mg or 200 mg twice daily compared with placebo in type 2 diabetic patients with inadequate glycemic control by diet therapy or combination of diet and exercise therapy.

Details

Lead sponsor	JW Pharmaceutical
Phase	Phase 3
Status	COMPLETED
Enrolment	117
Start date	2011-05
Completion	2012-11

Conditions

• Type 2 Diabetes Mellitus

Interventions

• Anagliptin
• Anagliptin
• Placebo of Anagliptin

Primary outcomes

• The Change in HbA1c from baseline to week24 — 0wk, 8wk, 16wk, 24wk

Countries

South Korea